RHB-102 (Bekinda®), an investigational drug, is a proprietary bimodal immediate and extended-release, once-daily oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist.
RHB-102 is in development for several gastrointestinal indications:
* Bekinda® is the proposed tradename for RHB-102, which is subject to review by the FDA at the time of NDA filing